Literature DB >> 8721781

The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients.

A Veves1, V M Donaghue, M R Sarnow, J M Giurini, D R Campbell, F W LoGerfo.   

Abstract

Hypoxia is considered to be one of the main aetiopathogenic factors of diabetic neuropathy. We have examined the effects of the reversal of hypoxia, achieved by revascularization, on peripheral nerve function in diabetic patients with or without clinical neuropathy. Fifty-six patients [mean age 62 (range 30-74) years, 44 (79%) males, 15 (27%) with insulin-dependent diabetes of 20 years (range 1-57) duration, and creatinine level 92.8 +/- 30.9 mumol/l (mean +/- SD)] were tested pre-operatively while 30 (54%) were reexamined at least 6 weeks post-operatively. At baseline the leg scheduled for operation showed worse measurements compared to the control leg when tested for Semmes-Weinstein monofilaments, peroneal motor conduction velocity (PMCV) (33.7 +/- 7.18 vs 35.7 +/- 6.09 m.s-1, p < 0.05) and transcutaneous oxygen tension (37.4 +/- 24.6 vs 52.0 +/- 21.5 mm Hg, p < 0.0001) while no differences were found in the vibration perception threshold and leg temperature. When baseline and post-operative measurements were later compared in the operated leg, no differences were noticed in the vibration perception threshold, PMCV and Semmes-Weinstein monofilaments but the transcutaneous oxygen tension increased significantly (32.7 +/- 27.1 vs 64.6 +/- 14.5 mm Hg, p < 0.001). No differences were noticed in any of the above parameters in the contralateral leg. No correlations were found between changes in transcutaneous oxygen tension and PMCV values measured at baseline and at the follow-up visit in either leg. Similar results were found when patients were stratified according to severity of neuropathy, ischaemia and the level of the bypass. We conclude that although there is greater impairment of nerve function in the more ischaemic leg, reversal of hypoxia does not result in any significant improvement of the nerve function measurements.

Entities:  

Mesh:

Year:  1996        PMID: 8721781     DOI: 10.1007/BF00418351

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  23 in total

1.  Endoneurial capillary abnormalities in mild human diabetic neuropathy.

Authors:  R A Malik; A Veves; E A Masson; A K Sharma; A K Ah-See; W Schady; R H Lye; A J Boulton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-07       Impact factor: 10.154

2.  Sural nerve oxygen tension in diabetes.

Authors:  P G Newrick; A J Wilson; J Jakubowski; A J Boulton; J D Ward
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-25

3.  Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration.

Authors:  S Kumar; D J Fernando; A Veves; E A Knowles; M J Young; A J Boulton
Journal:  Diabetes Res Clin Pract       Date:  1991-08       Impact factor: 5.602

4.  Improvement in nerve conduction following treatment in newly diagnosed diabetics.

Authors:  J D Ward; C G Barnes; D J Fisher; J D Jessop; R W Baker
Journal:  Lancet       Date:  1971-02-27       Impact factor: 79.321

5.  Peripheral neuropathy in chronic disease of the respiratory tract.

Authors:  O Appenzeller; R D Parks; J MacGee
Journal:  Am J Med       Date:  1968-06       Impact factor: 4.965

6.  The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests.

Authors:  P J Dyck; K M Kratz; K A Lehman; J L Karnes; L J Melton; P C O'Brien; W J Litchy; A J Windebank; B E Smith; P A Low
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

Review 7.  Vascular factors in diabetic neuropathy.

Authors:  S Tesfaye; R Malik; J D Ward
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

Review 8.  Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? The 1988 Robert Wartenberg lecture.

Authors:  P J Dyck
Journal:  Neurology       Date:  1989-01       Impact factor: 9.910

9.  Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy.

Authors:  P J Dyck; A Lais; J L Karnes; P O'Brien; R Rizza
Journal:  Ann Neurol       Date:  1986-05       Impact factor: 10.422

10.  Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy.

Authors:  P J Dyck; J L Karnes; J Daube; P O'Brien; F J Service
Journal:  Brain       Date:  1985-12       Impact factor: 13.501

View more
  5 in total

Review 1.  Inflammation: therapeutic targets for diabetic neuropathy.

Authors:  Jiyin Zhou; Shiwen Zhou
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

2.  [Diabetes, heart surgery and the peripheral arteries].

Authors:  C Diehm; H Lawall
Journal:  Clin Res Cardiol       Date:  2006-01       Impact factor: 5.460

Review 3.  Toxic stress, inflammation and symptomatology of chronic complications in diabetes.

Authors:  Charles A Downs; Melissa Spezia Faulkner
Journal:  World J Diabetes       Date:  2015-05-15

Review 4.  Declining Skeletal Muscle Function in Diabetic Peripheral Neuropathy.

Authors:  Prodromos Parasoglou; Smita Rao; Jill M Slade
Journal:  Clin Ther       Date:  2017-05-30       Impact factor: 3.393

5.  Is cardiovascular disease a risk factor in the development of axonal polyneuropathy?

Authors:  L L Teunissen; H Franssen; J H J Wokke; Y van der Graaf; W H J P Linssen; J D Banga; D M Laman; N C Notermans
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.